MaaT013 as Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

Conditions:   Acute Graft Versus Host Disease in Intestine;   Steroid Refractory GVHD Intervention:   Drug: MaaT013 Sponsor:   MaaT Pharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials